Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with Neuroendocrine Tumor
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients with suspected or clearly diagnosed Neuroendocrine Tumor
• signed written consent.
• Willing and able to cooperate with all projects in this study.
Locations
Other Locations
China
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING
Beijing
Contact Information
Primary
Gouzhu Hou, M.D.
15611145656@163.com
15611145656
Backup
Xin Cheng, M.D.
cxpumc@foxmail.com
15120002998
Time Frame
Start Date: 2022-12-20
Estimated Completion Date: 2025-12-20
Participants
Target number of participants: 400
Treatments
Experimental: Al18F-octreotide PET/CT
Al18F-octreotide PET/CT will be performed on patients with suspected or clearly diagnosed Neuroendocrine Tumor. The patients were injected with Al18F-octreotide and underwent PET/CT scan 20\~40min after the injection.
Related Therapeutic Areas
Sponsors
Leads: Cancer Institute and Hospital, Chinese Academy of Medical Sciences